Anieta M Sieuwerts

List of Publications by Year
in descending order

135 papers	17,273 citations	30070 54 h-index	14759 127 g-index
138 all docs	138 docs citations	138 times ranked	24606 citing authors

#	Article	IF	Citations
1	Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, The, 2005, 365, 671-679.	13.7	2,452
2	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	27.8	1,760
3	The Life History of 21 Breast Cancers. Cell, 2012, 149, 994-1007.	28.9	1,249
4	Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature, 2009, 462, 1005-1010.	27.8	776
5	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature Medicine, 2017, 23, 517-525.	30.7	769
6	Subtypes of Breast Cancer Show Preferential Site of Relapse. Cancer Research, 2008, 68, 3108-3114.	0.9	674
7	Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell, 2017, 32, 169-184.e7.	16.8	534
8	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	5.5	526
9	Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. Journal of the National Cancer Institute, 2009, 101, 61-66.	6.3	407
10	Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13021-13026.	7.1	374
11	Multicenter Validation of a Gene Expressionâ€“Based Prognostic Signature in Lymph Nodeâ€“Negative Primary Breast Cancer. Journal of Clinical Oncology, 2006, 24, 1665-1671.	1.6	328
12	Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling. Journal of Clinical Oncology, 2005, 23, 732-740.	1.6	322
13	Genes Associated With Breast Cancer Metastatic to Bone. Journal of Clinical Oncology, 2006, 24, 2261-2267.	1.6	278
14	The topography of mutational processes in breast cancer genomes. Nature Communications, 2016, 7, 11383.	12.8	235
15	Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. European Urology, 2015, 68, 939-945.	1.9	223
16	mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients. Clinical Cancer Research, 2011, 17, 3600-3618.	7.0	207
17	Plasticity of Lgr5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer. Cell Stem Cell, 2020, 26, 569-578.e7.	11.1	180
18	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Science Advances, 2016, 2, e1601737.	10.3	175

#	Article	IF	Citations
19	Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Research and Treatment, 2009, 118, 455-468.	2.5	171
20	CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget, 2013, 4, 1748-1762.	1.8	169
21	Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response. Clinical Cancer Research, 2008, 14, 5555-5564.	7.0	155
22	Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. British Journal of Cancer, 2013, 108, 1358-1367.	6.4	148
23	Functional Ex Vivo Assay to Select Homologous Recombinationâ€“Deficient Breast Tumors for PARP Inhibitor Treatment. Clinical Cancer Research, 2014, 20, 4816-4826.	7.0	144
24	Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers. Hormones and Cancer, 2014, 5, 405-413.	4.9	140
25	The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Research and Treatment, 2009, 116, 303-309.	2.5	134
26	<scp>KRAS</scp> and <scp>BRAF</scp> mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. International Journal of Cancer, 2013, 133, 130-141.	5.1	128
27	MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Research and Treatment, 2011, 127, 43-51.	2.5	127
28	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nature Communications, 2016, 7, 12910.	12.8	119
29	HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study. Journal of Clinical Oncology, 2007, 25, 662-668.	1.6	118
30	Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. British Journal of Cancer, 2010, 103, 1284-1291.	6.4	111
31	Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Research and Treatment, 2011, 127, 33-41.	2.5	110
32	Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Research and Treatment, 2013, 138, 47-57.	2.5	110
33	Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer, 2007, 7, 182.	2.6	109
34	Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons. BMC Bioinformatics, 2018, 19, 236.	2.6	105
35	Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer. Cancer Research, 2005, 65, 4101-4117.	0.9	104
36	DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Research and Treatment, 2008, 111, 429-437.	2.5	103

#	Article	IF	Citations
37	Circulating tumour cell detection on its way to routine diagnostic implementation?. European Journal of Cancer, 2007, 43, 2645-2650.	2.8	101
38	Relevance of Breast Cancer Antiestrogen Resistance Genes in Human Breast Cancer Progression and Tamoxifen Resistance. Journal of Clinical Oncology, 2009, 27, 542-549.	1.6	93
39	The circular RNome of primary breast cancer. Genome Research, 2019, 29, 356-366.	5.5	85
40	Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Research and Treatment, 2011, 128, 23-30.	2.5	83
41	LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. Endocrine-Related Cancer, 2014, 21, 101-112.	3.1	82
42	Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus. PLoS Genetics, 2010, 6, e1001029.	3.5	82
43	How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study. Clinical Cancer Research, 2005, 11, 7311-7321.	7.0	78
44	Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2014, 106, djt376.	6.3	77
45	Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Nodeâ€“Negative Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 3319-3328.	7.0	76
46	A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. Cancer Research, 2017, 77, 3814-3822.	0.9	76
47	Copy Number Alterations that Predict Metastatic Capability of Human Breast Cancer. Cancer Research, 2009, 69, 3795-3801.	0.9	75
48	Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics, 2009, 10, 424.	2.8	74
49	Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Review of Molecular Diagnostics, 2011, 11, 259-275.	3.1	70
50	KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival. Science Translational Medicine, 2013, 5, 169ra12.	12.4	70
51	Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thrombosis and Haemostasis, 2003, 89, 393-404.	3.4	69
52	High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 133, 937-947.	2.5	65
53	Decreased expression of ABAT and STC2 hallmarks ERâ€positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Molecular Oncology, 2015, 9, 1218-1233.	4.6	64
54	T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression. Acta Neuropathologica, 2018, 135, 581-599.	7.7	63

#	Article	IF	Citations
55	BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. British Journal of Cancer, 2012, 107, 947-955.	6.4	61
56	Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocrine-Related Cancer, 2008, 15, 101-111.	3.1	59
57	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2016, 22, 4746-4755.	7.0	59
58	Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Research and Treatment, 2008, 111, 229-240.	2.5	55
59	Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. Clinical Cancer Research, 2018, 24, 6277-6287.	7.0	53
60	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. Molecular Oncology, 2018, 12, 48-57.	4.6	52
61	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Molecular Cancer Therapeutics, 2015, 14, 821-827.	4.1	49
62	In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer. Journal of Nuclear Medicine, 2015, 56, 752-757.	5.0	49
63	CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Letters, 2012, 319, 49-55.	7.2	48
64	A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. Journal of Thrombosis and Haemostasis, 2012, 10, 931-939.	3.8	48
65	Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. European Journal of Cancer, 2021, 150, 179-189.	2.8	47
66	Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Research and Treatment, 2011, 125, 387-394.	2.5	46
67	Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes. Breast Cancer Research and Treatment, 2012, 133, 843-851.	2.5	46
68	Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Annals of Oncology, 2015, 26, 510-516.	1.2	46
69	Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation. Nature Communications, 2019, 10, 1749.	12.8	46
70	Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia, 2016, 18, 647-653.	5.3	44
71	Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. Cancer Letters, 2015, 362, 36-44.	7.2	41
72	High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. Breast Cancer Research, 2012, 14, R123.	5.0	38

#	Article	IF	Citations
73	CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. British Journal of Cancer, 2009, 101, 1824-1832.	6.4	37
74	Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. Breast Cancer Research and Treatment, 2012, 132, 439-448.	2.5	37
75	mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. Molecular Oncology, 2015, 9, 920-932.	4.6	37
76	Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. Oncotarget, 2016, 7, 59058-59069.	1.8	37
77	Protein kinase Cĵ expression in breast cancer as measured by real-time PCR, western blotting and ELISA. British Journal of Cancer, 2008, 99, 1644-1650.	6.4	35
78	Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer. Breast Cancer Research and Treatment, 2009, 116, 263-271.	2.5	35
79	Allele-Specific, Non-Extendable Primer Blocker PCR (AS-NEPB-PCR) for DNA Mutation Detection in Cancer. Journal of Molecular Diagnostics, 2013, 15, 62-69.	2.8	35
80	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene, 2017, 36, 2737-2749.	5.9	34
81	Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer. Scientific Reports, 2017, 7, 2099.	3.3	33
82	Confirmation of a metastasis-specific microRNA signature in primary colon cancer. Scientific Reports, 2018, 8, 5242.	3.3	33
83	Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis. Oncotarget, 2016, 7, 29166-29176.	1.8	33
84	Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer. Scientific Reports, 2018, 8, 9657.	3.3	32
85	Concentrations of TIMP1 mRNA Splice Variants and TIMP-1 Protein Are Differentially Associated with Prognosis in Primary Breast Cancer. Clinical Chemistry, 2007, 53, 1280-1288.	3.2	31
86	Progressive APOBEC3B mRNA expression in distant breast cancer metastases. PLoS ONE, 2017, 12, e0171343.	2.5	31
87	Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocrine-Related Cancer, 2010, 17, 215-230.	3.1	30
88	Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy. Journal of Nuclear Medicine, 2015, 56, 1487-1493.	5.0	30
89	Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancer. EBioMedicine, 2019, 48, 212-223.	6.1	29
90	Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer. Cancer Letters, 2015, 356, 872-879.	7.2	28

#	Article	IF	Citations
91	Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. International Journal of Cancer, 2019, 145, 1083-1089.	5.1	27
92	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. BMC Cancer, 2016, 16, 123.	2.6	25
93	TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. Breast Cancer Research and Treatment, 2009, 113, 253-260.	2.5	24
94	The Influence of Tissue Procurement Procedures on RNA Integrity, Gene Expression, and Morphology in Porcine and Human Liver Tissue. Biopreservation and Biobanking, 2015, 13, 200-206.	1.0	23
95	Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer. American Journal of Pathology, 2017, 187, 1648-1655.	3.8	23
96	AR splice variants in circulating tumor cells of patients with castrationâ€resistant prostate cancer: relation with outcome to cabazitaxel. Molecular Oncology, 2019, 13, 1795-1807.	4.6	23
97	GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. Cancer Letters, 2016, 376, 104-109.	7.2	22
98	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. Cancers, 2019, 11, 1212.	3.7	21
99	Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study. Breast Cancer Research, 2010, 12, R103.	5.0	20
100	Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2019, 121, 48-54.	2.8	20
101	ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen. Cancers, 2020, 12, 802.	3.7	20
102	The challenge of gene expression profiling in heterogeneous clinical samples. Methods, 2013, 59, 47-58.	3.8	18
103	Evaluation of the ability of adjuvant tamoxifenâ€benefit gene signatures to predict outcome of hormoneâ€naive estrogen receptorâ€positive breast cancer patients treated with tamoxifen in the advanced setting. Molecular Oncology, 2014, 8, 1679-1689.	4.6	18
104	Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer. BMC Cancer, 2021, 21, 315.	2.6	18
105	Integrative Analysis of Genomics and Proteomics Data on Clinical Breast Cancer Tissue Specimens Extracted with Acid Guanidinium Thiocyanateâ€“Phenolâ€“Chloroform. Journal of Proteome Research, 2015, 14, 1627-1636.	3.7	17
106	PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. Endocrine-Related Cancer, 2019, 26, 471-482.	3.1	17
107	DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERÎ±-positive breast cancer cells. Breast Cancer Research and Treatment, 2015, 149, 693-703.	2.5	16
108	Proper genomic profiling of (BRCA1â€mutated) basalâ€like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. Molecular Oncology, 2015, 9, 877-888.	4.6	16

#	Article	IF	Citations
109	Dendritic Cells Actively Limit Interleukin-10 Production Under Inflammatory Conditions via DC-SCRIPT and Dual-Specificity Phosphatase 4. Frontiers in Immunology, 2018, 9, 1420.	4.8	16
110	The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer. PLoS ONE, 2016, 11, e0161731.	2.5	15
111	An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. Journal of Molecular Diagnostics, 2018, 20, 316-325.	2.8	15
112	An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA. Journal of Molecular Diagnostics, 2019, 21, 123-137.	2.8	15
113	Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. Clinical Cancer Research, 2017, 23, 4735-4743.	7.0	14
114	High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. PLoS ONE, 2017, 12, e0185607.	2.5	14
115	Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. BMC Cancer, 2020, 20, 850.	2.6	14
116	Multiplex Molecular Analysis of CTCs. Recent Results in Cancer Research, 2012, 195, 125-140.	1.8	14
117	Optimization of Pancreatic Juice Collection: A First Step Toward Biomarker Discovery and Early Detection of Pancreatic Cancer. American Journal of Gastroenterology, 2020, 115, 2103-2108.	0.4	14
118	Analysis of clonal expansions through the normal and premalignant human breast epithelium reveals the presence of luminal stem cells. Journal of Pathology, 2018, 244, 61-70.	4.5	13
119	Overexpression of Colligin 2 in Glioma Vasculature is Associated with Overexpression of Heat shock Factor 2. Gene Regulation and Systems Biology, 2010, 4, GRSB.S4546.	2.3	12
120	MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer. Oncotarget, 2018, 9, 24335-24346.	1.8	11
121	Response: Re: Antiâ€“Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. Journal of the National Cancer Institute, 2009, 101, 896-897.	6.3	10
122	mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy. Molecular Oncology, 2016, 10, 1542-1550.	4.6	9
123	APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer. Cancers, 2019, 11, 1062.	3.7	9
124	Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. Oncogene, 2022, 41, 3498-3506.	5.9	9
125	Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer. PLoS ONE, 2017, 12, e0170536.	2.5	8
126	The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer. BMC Cancer, 2022, 22, 165.	2.6	8

#	Article	IF	Citations
127	Hormone replacement therapy dependent changes in breast cancerâ€related gene expression in breast tissue of healthy postmenopausal women. Molecular Oncology, 2011, 5, 504-516.	4.6	7
128	A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds. PLoS ONE, 2015, 10, e0144097.	2.5	6
129	A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity. Molecular Oncology, 2022, 16, 2981-3000.	4.6	6
130	Shotgun Proteomics on Tissue Specimens Extracted with Acid Guanidinium-Thiocyanate-Phenol-Chloroform. Methods in Molecular Biology, 2015, 1293, 115-122.	0.9	4
131	Proteome-wide onco-proteogenomic somatic variant identification in ER-positive breast cancer. Clinical Biochemistry, 2019, 66, 63-75.	1.9	3
132	A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study.. Journal of Clinical Oncology, 2013, 31, e22106-e22106.	1.6	1
133	Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 697572.	2.8	0
134	mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AI).. Journal of Clinical Oncology, 2013, 31, 11045-11045.	1.6	0
135	Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, 11017-11017.	1.6	0